Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Papachristofilou, Alexandros; Hipp, M.; Klinkhardt, Ute; Früh, Martin; Sebastian, Martin; Weiß, Christian; Pless, Miklos; Cathomas, Richard; Hilbe, Wolfgang; Pall, Georg; Wehler, Thomas; Alt, Jürgen; Bischoff, Helge; Geißler, Michael; Griesinger, Frank; Kallen, Karl‐Josef; Fotin‐Mleczek, Mariola; Schröder, Andreas; Scheel, Birgit; Muth, Anke; Seibel, Tobias; Stosnach, Claudia; Doener, Fatma; S. Hong, Henoch; D. Koch, Sven; Gnad-Vogt, Ulrike; Zippelius, Alfred

doi:10.1186/s40425-019-0520-5

Public

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Published in Journal for ImmunoTherapy of Cancer • Feb 8, 2019

Authors:

Alexandros Papachristofilou

M. Hipp

Ute Klinkhardt

Abstract

BACKGROUND: Preclinical studies demonstrate synergism between cancer immunotherapy and local radiation, enhancing anti-tumor effects and promoting immune responses. BI1361849 (CV9202) is an active cancer immunotherapeutic comprising protamine-formulated, sequence-optimized mRNA encoding six non-smal...

Subject

Medicine

Lung cancer

Pemetrexed

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!